Evercore ISI Group Maintains In-Line on Hims & Hers Health, Raises Price Target to $27
Benzinga Newsdesk 7 hours ago
Analyst RatingsNewsPrice Target
Evercore ISI Group analyst Mark Mahaney maintains Hims & Hers Health (NYSE:HIMS) with a In-Line and raises the price target from $24 to $27.
Evercore ISI Group analyst Mark Mahaney maintains Hims & Hers Health (NYSE:HIMS) with a In-Line and raises the price target from $24 to $27.